Clinical trial
Immunogenicity and Safety of Pentaxim™ in an Indian Population
NCT00259337 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00259337 |
|---|---|
| Title | Immunogenicity and Safety of Pentaxim™ in an Indian Population |
| Official title | Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Polio, Pertussis, Haemophilus Infections |
| Intervention type | Biological |
| Interventions | Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine |
| Enrollment | 226 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Nov 29, 2005 |
| Last update posted | Apr 16, 2012 |
| Countries | India |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: